Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial — Petr Widimský (2023) | RDL Network
John W. Eikelboom, Deepak L. Bhatt, Keith A.A. Fox, Jackie Bosch, Stuart J. Connolly, Sonia S. Anand, Álvaro Avezum, Scott D. Berkowitz, Kelley R. Branch, Gilles R. Dagenais, Camilo Félix, Tomasz J. Guzik, Robert G. Hart, Aldo Maggioni, Eva Muehlhofer, Mukul Sharma, Olga Shestakovska, Salim Yusuf
Kelley R. Branch, Jeffrey L. Probstfield, John W. Eikelboom, Jackie Bosch, Aldo Maggioni, Richard K. Cheng, Deepak L. Bhatt, Álvaro Avezum, Keith A.A. Fox, Stuart J. Connolly, Olga Shestakovska, Salim Yusuf
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Jessica Tyrwitt, Keith A.A. Fox, Eva Muehlhofer, Christoph Neumann, Christoph Tasto, Shrikant I. Bangdiwala, Rafael Díaz, Marco Alings, Gilles R. Dagenais, Darryl P. Leong, Eva Lonn, Álvaro Avezum, Leopoldo Soares Piegas, Petr Widimský, Alexander Parkhomenko, Deepak L. Bhatt, Kelley R. Branch, Jeffrey L. Probstfield,
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Olga Shestakovska, Gilles R. Dagenais, Robert G. Hart, Darryl P. Leong, Martin O’Donnell, Keith A.A. Fox, Deepak L. Bhatt, John A. Cairns, Christoph Tasto, Scott D. Berkowitz, Nancy Cook Bruns, Eva Muehlhofer, Rafael Díaz, Aldo Maggioni, Salim Yusuf
Discussion(0)
No comments yet. Be the first to comment.